Update shared on 01 Dec 2025
Fair value Decreased 14%Analysts have revised their fair value estimate for Cohance Lifesciences downward from ₹930 to ₹801.11, citing slightly reduced expectations for revenue growth and profit margin projections.
What's in the News
- Cohance Lifesciences has provided revenue guidance for 2030, with a target of USD 1 billion (INR 85 billion) in revenue. (Company guidance)
- The resignation of Dr. V Prasada Raju as Managing Director was approved and will be effective on October 28, 2025. He will continue to support the company to ensure a smooth transition. (Board of Directors meeting)
- A board meeting is scheduled for November 12, 2025, to consider and approve the unaudited financial results for the quarter and half year ending September 30, 2025. The meeting will also review related reports and press releases. (Company announcement)
Valuation Changes
- The Fair Value Estimate has decreased from ₹930 to ₹801.11, reflecting a notable downward revision.
- The Discount Rate remains unchanged at 12.76%.
- Revenue Growth projections have fallen slightly from 59.10% to 56.65%.
- The Net Profit Margin expectation has decreased from 21.68% to 20.43%.
- The estimated Future P/E Ratio is now 56.40x, down from the previous 58.91x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.